Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new

On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patien

On January 16, 2020, the Italian pharmaceutical company Recordati recently announced that the Europe

On March 17th, the State Council's joint prevention and control mechanism held a press conferenc

2020.02.27, Biohaven announced that the US FDA has approved the company's CGRP receptor inhibito

Dayvigo (lembroexant) developed by Eisai is an orexin receptor antagonist. Orexin is a neuropeptide

Recently, the US FDA announced that it has approved the listing of the calcitonin gene-related pepti

Novartis recently announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22

November 22, 2019, Roche announces data from positive studies of the IMbrave 150 phase III clinical

Flumatinib is a tyrosine kinase inhibitor and it’s a second-generation TK inhibitor drug against Bcr